NASDAQ:SLDB Solid Biosciences (SLDB) Stock Price, News & Analysis $9.29 +0.24 (+2.65%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$9.12▼$9.6450-Day Range$5.67▼$9.6452-Week Range$1.81▼$15.05Volume250,951 shsAverage Volume383,996 shsMarket Capitalization$356.55 millionP/E RatioN/ADividend YieldN/APrice Target$16.17 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Solid Biosciences alerts: Email Address Solid Biosciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.11 Rating ScoreUpside/Downside74.0% Upside$16.17 Price TargetShort InterestHealthy5.23% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.31Based on 5 Articles This WeekInsider TradingAcquiring Shares$8,437 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($2.71) to ($2.78) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.81 out of 5 starsMedical Sector238th out of 936 stocksBiological Products, Except Diagnostic Industry31st out of 154 stocks 4.6 Analyst's Opinion Consensus RatingSolid Biosciences has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSolid Biosciences has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Solid Biosciences' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted5.23% of the float of Solid Biosciences has been sold short.Short Interest Ratio / Days to CoverSolid Biosciences has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Solid Biosciences has recently decreased by 45.57%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSolid Biosciences does not currently pay a dividend.Dividend GrowthSolid Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SLDB. Previous Next 1.8 News and Social Media Coverage News SentimentSolid Biosciences has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Solid Biosciences this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for SLDB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Solid Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Solid Biosciences insiders have bought 76.80% more of their company's stock than they have sold. Specifically, they have bought $8,437.00 in company stock and sold $4,772.00 in company stock.Percentage Held by Insiders13.63% of the stock of Solid Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions81.46% of the stock of Solid Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Solid Biosciences' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Solid Biosciences are expected to decrease in the coming year, from ($2.71) to ($2.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Solid Biosciences is -2.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Solid Biosciences is -2.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSolid Biosciences has a P/B Ratio of 1.48. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Solid Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Solid Biosciences Stock (NASDAQ:SLDB)Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.Read More SLDB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SLDB Stock News HeadlinesJuly 20, 2024 | americanbankingnews.comSolid Biosciences Inc. (NASDAQ:SLDB) to Post Q2 2024 Earnings of ($0.69) Per Share, Leerink Partnrs ForecastsJuly 1, 2024 | globenewswire.comSolid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)July 27, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.June 4, 2024 | globenewswire.comSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 20, 2024 | markets.businessinsider.comBuy Rating for Solid Biosciences Anchored on Robust Financials and Promising Clinical ProspectsMay 20, 2024 | investorplace.com3 Must-Buy Biotech Stocks Before the Summer Rally Kicks OffMay 15, 2024 | msn.comSolid Biosciences reports Q1 resultsMay 15, 2024 | investorplace.comSLDB Stock Earnings: Solid Biosciences Meets EPS for Q1 2024July 27, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 15, 2024 | globenewswire.comSolid Biosciences Provides First Quarter 2024 Business Update and Financial ResultsMay 2, 2024 | globenewswire.comSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 10, 2024 | seekingalpha.comBuy Solid Biosciences: Unpacking Its Main Value DriverApril 3, 2024 | globenewswire.comSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 1, 2024 | markets.businessinsider.comSolid Biosciences: FDA Grants Rare Pediatric Disease Designation For SGT-003April 1, 2024 | globenewswire.comSolid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003March 28, 2024 | msn.comWilliam Blair starts Solid Biosciences at outperformMarch 27, 2024 | finance.yahoo.comSolid Biosciences to Participate at Cantor’s Virtual Muscular Dystrophy SymposiumMarch 24, 2024 | finance.yahoo.comSLDB Apr 2024 7.500 putSee More Headlines Receive SLDB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Solid Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today7/26/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SLDB CUSIPN/A CIK1707502 Webwww.solidbio.com Phone(617) 337-4680FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Stock Price Target$16.17 High Stock Price Target$20.00 Low Stock Price Target$12.00 Potential Upside/Downside+74.0%Consensus RatingBuy Rating Score (0-4)3.11 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($3.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-96,010,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-55.94% Return on Assets-44.95% Debt Debt-to-Equity Ratio0.01 Current Ratio14.94 Quick Ratio14.94 Sales & Book Value Annual Sales$8.09 million Price / Sales44.07 Cash FlowN/A Price / Cash FlowN/A Book Value$6.27 per share Price / Book1.48Miscellaneous Outstanding Shares38,380,000Free Float33,148,000Market Cap$356.55 million OptionableOptionable Beta1.85 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Ian F. Smith A.C.A. (Age 58)C.P.A., Executive Chair Comp: $75kMr. Alexander G. Cumbo (Age 53)President, CEO & Director Comp: $918.55kMr. Ilan Ganot (Age 50)Co-founder, Strategic Advisor to the CEO & Director Comp: $847.87kMr. Kevin Tan C.F.A. (Age 46)CFO & Treasurer Comp: $607.18kMr. David Tyronne Howton Jr. (Age 52)J.D., COO, General Counsel & Secretary Comp: $648.88kMs. Annie GanotCo-Founder & Head of Patient AdvocacyMr. Paul Herzich (Age 46)Chief Technology Officer Dr. Jennifer Marlowe Ph.D. (Age 47)Chief Scientific Officer Ms. Allison Bogosian J.D.Senior Vice President of Human ResourcesDr. Jessie Hanrahan Ph.D. (Age 48)Chief Regulatory Officer More ExecutivesKey CompetitorsLogicBio TherapeuticsNASDAQ:LOGCChampions OncologyNASDAQ:CSBRSana BiotechnologyNASDAQ:SANADay One BiopharmaceuticalsNASDAQ:DAWNANI PharmaceuticalsNASDAQ:ANIPView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 69,107 shares on 7/26/2024Ownership: 0.180%Clare KahnBought 1,100 shares on 6/7/2024Total: $8,437.00 ($7.67/share)RA Capital Management L.P.Bought 904,160 shares on 5/17/2024Ownership: 11.438%Artal Group S.A.Bought 1,590,781 shares on 5/17/2024Ownership: 6.603%Bain Capital Life Sciences Investors LLCBought 904,160 shares on 5/16/2024Ownership: 10.657%View All Insider TransactionsView All Institutional Transactions SLDB Stock Analysis - Frequently Asked Questions How have SLDB shares performed this year? Solid Biosciences' stock was trading at $6.14 at the start of the year. Since then, SLDB stock has increased by 51.3% and is now trading at $9.29. View the best growth stocks for 2024 here. How were Solid Biosciences' earnings last quarter? Solid Biosciences Inc. (NASDAQ:SLDB) released its earnings results on Wednesday, May, 15th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.57) by $0.07. When did Solid Biosciences' stock split? Shares of Solid Biosciences reverse split on Friday, October 28th 2022. The 1-15 reverse split was announced on Friday, October 28th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, October 28th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Solid Biosciences IPO? Solid Biosciences (SLDB) raised $130 million in an initial public offering on Friday, January 26th 2018. The company issued 7,000,000 shares at a price of $18.00-$19.00 per share. J.P. Morgan, Goldman Sachs and Leerink Partners served as the underwriters for the IPO and Nomura and Chardan were co-managers. Who are Solid Biosciences' major shareholders? Solid Biosciences' top institutional shareholders include Bank of New York Mellon Corp (0.18%). Insiders that own company stock include Perceptive Advisors Llc, Carl Ashley Morris, Alexander Cumbo, Ilan Ganot, Jessie Hanrahan, Paul Herzich, Clare Kahn and Joel Solomon Zev Schneider. View institutional ownership trends. How do I buy shares of Solid Biosciences? Shares of SLDB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Solid Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Solid Biosciences investors own include Selecta Biosciences (SELB), VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Amarin (AMRN), Catalyst Pharmaceuticals (CPRX) and Cidara Therapeutics (CDTX). This page (NASDAQ:SLDB) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Solid Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Solid Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
